For acute kidney injury, inflammatory bowel disease, depressions, etc.
Peptide linker enhances the interaction between VH-VL within scFv molecules, which suppresses intermolecular association.
A new therapeutic concept to prevent cellular infiltration into inflamed tissues by targeting the nets structures (Myl9-nets) generated in the lumen of blood vessels.
Mechanism that utilizes the phenomenon of drug release through the process of water solubilization of gas enclosed in the device.
Oral insulin formulation with peptide DDS technology for high intestinal absorption efficiency.
Peptide vaccine that induces CTLs (cytotoxic T cells) targeting the nucleocapsid-derived epitope of SARS-CoV-2.
Endogenous protein that promotes adipocyte activation (UCP1 expression promotion/mitochondrial activation).
TribsMab CLC, a novel bispecific antibody format solves a manufacturing challenge
Therapeutic mechanism that differs from conventional treatment methods with the target identified from genetic analysis of model animals and IC patients
Designed RANKL fragment peptides (Partial agonist of RANKL) treat fibrosis.
Blockade of novel target, Netrin-4 Unc5B signaling.
A new therapeutic mechanism to inhibit cytokine production from topical IL-17-producing cells by CD96 neutralizing antibodies
Treatment of immunological diseases by a new mechanism to control the immune Th1/Th2 balance
Original method and hepatocyte reproduced hepatobiliary function
A novel technology loosens tight junction of BBB and supports drug transportation into brain.
Selective inhibition of Periostin variant (PN1) by monoclonal antibody
Variant Specific Periostin Neutralization for Diabetic Retinopathy